BPC-157 (10mg)
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a gastric protein sequence and is studied for its tissue healing and cytoprotective properties. Preclinical models show accelerated wound healing and anti-inflammatory action, though human clinical data remain limited. This protocol outlines a once-daily subcutaneous approach using the 10 mg vial.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
Research monograph
See the full BPC-157 encyclopedia page with mechanism, evidence tier, related variants and research context.
How It Works
BPC-157 is a synthetic peptide corresponding to a partial sequence of a human gastric juice protein. Preclinical studies suggest it modulates nitric oxide pathways and growth factor expression to promote angiogenesis and collagen deposition in damaged tissues. Animal models report accelerated healing of intestinal, tendon, ligament, and muscle injuries. A Phase I safety trial (oral) has been completed; however, large-scale, controlled efficacy data is not yet available.
Quick Start
- Reconstitution: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.
- Typical Daily Range: 200–600 mcg once daily (gradual titration).
- Storage: Lyophilized: freezer at −20 °C; post-reconstitution, refrigerator at 2–8 °C; avoid freeze-thaw cycles.
Standard / Titration Approach (3 mL = ~3.33 mg/mL)
Route: Subcutaneous | Frequency: Once daily
| Week | Dose | Units (per injection) |
|---|---|---|
| Weeks 1–2 | 200 mcg (0.2 mg) | 6 Units (0.06 mL) |
| Weeks 3–4 | 400 mcg (0.4 mg) | 12 Units (0.12 mL) |
| Weeks 5–8+ | 600 mcg (0.6 mg) | 18 Units (0.18 mL) |
Studies report administration once daily subcutaneously. Dosing is estimated from preclinical models; human clinical validation remains limited.
Related compounds
Reconstitution Steps
- Withdraw 3.0 mL of bacteriostatic water.
- Inject slowly down the side of the vial; avoid foaming.
- Gently swirl/rotate until dissolved (do not shake vigorously).
- Label and refrigerate at 2–8 °C, protected from light.
Protocol Overview
- Goal: Support tissue healing and recovery processes based on preclinical data.
- Schedule: Daily subcutaneous injections for 8–12 weeks (extendable to 16 weeks if needed).
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid freeze-thaw.
Dosing Protocol
- Initiation: 200 mcg daily; increase by ~200 mcg every 2 weeks.
- Target: 400–600 mcg daily by weeks 5–8+.
- Frequency: Once daily (subcutaneously).
- Cycle Duration: 8–12 weeks; optional extension to 16.
- Timing: Any consistent time; rotate sites.
- Break between cycles: After a cycle, a 2–4 week washout period is recommended before repeating. BPC-157 has a short half-life—the break helps prevent potential tachyphylaxis.
Washout & Cycle Restart
When can I restart?
After a cycle, a 2–4 week washout period is recommended before repeating. BPC-157 has a short half-life—the break helps prevent potential tachyphylaxis.
Minimum wait period: 2 weeks
Storage Instructions
- Lyophilized: Store at −20 °C in dry, dark conditions.
- Reconstituted: Refrigerate at 2–8 °C; avoid freeze-thaw cycles.
- Allow vials to reach room temperature before opening.
Important Notes
- Human data on BPC-157 is preliminary; consult a specialist.
Potential Benefits & Side Effects
Potential Benefits:
- Supports tissue healing in intestinal, tendon, muscle, and skin injury models (animal data).
- Exhibits anti-inflammatory and cytoprotective properties in preclinical studies.
- Phase I safety studies report good tolerability with no serious adverse events.
- Occasional mild injection site reactions (redness, itching).
- Long-term human safety and efficacy are under investigation.
Potential Side Effects:
- Injection site reactions: redness, swelling, stinging (15–25%).
- Transient nausea (5–10%, mainly the first week).
- Dizziness (3–7%, rare).
- Human clinical data is very limited.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Theoretical concern: angiogenesis & oncogenesis
BPC-157 promotes angiogenesis (VEGF upregulation). May theoretically enhance blood supply to existing tumors. No clinical data in humans.
📄 J Physiol Pharmacol 2010References
- Journal of Pharmacological Sciences — BPC-157 promotes healing via NO regulation
View Source - Pharmaceuticals (MDPI, 2025) — Multifunctionality of BPC-157: a literature review
View Source - Current Pharmaceutical Design (PMC) — BPC-157 stable gastric pentadecapeptide: healing therapy
View Source - Life Sciences — BPC-157 and angiogenic growth factors
View Source - Journal of Orthopaedic Research — BPC-157 promotes tendon-to-bone healing in a rat model
View Source
Recommended Supplements
Curcumin (Turmeric Extract)
Collagen Peptides
External Sources & Regulatory Status
Regulatory Approvals
Research-only — No regulatory approval (extensive preclinical research)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →